STAT+: AbbVie sues a behind-the-scenes company for exploiting its patient assistance program
AbbVie has filed a lawsuit against a behind-the-scenes company that helps health plan sponsors take…
Category: Pharma
STAT+: Senate panel passes a suite of drug pricing bills — but fails to advance one major PBM reform
WASHINGTON – The Senate health committee on Thursday passed a package of bills aimed at…
STAT+: Wyden decries ‘astonishingly low’ tax rates for pharma companies as he probes business maneuvers
Thanks to changes in tax law six years ago, several of the largest pharmaceutical companies…
STAT+: Pharmalittle: FDA panel recommends first OTC birth control pill; Senate hearing on insulin costs satisfies no one
Hello, everyone, and how are you today? We are doing just fine, thank you, as…
STAT+: Telework helps FDA compete for scientists. What if it’s no longer an option?
WASHINGTON — The Food and Drug Administration needs to hire scores of in-demand scientists, and…
STAT+: Insulin makers, PBMs echo old finger-pointing in Senate hearing
A Senate hearing on high insulin costs billed as a blockbuster showdown with drugmakers and…
FDA panel votes in favor of the first-ever over-the-counter birth control pill
In a highly significant move, a panel of independent experts on Wednesday voted unanimously that…
STAT+: Pharmalittle: Gilead wins lawsuit against HHS over HIV pill patents; most Americans say abortion pill should remain on the market
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: In small study, weight loss drug boosts immune cells that help fight cancer
Drugs like Ozempic and Wegovy have become immensely popular for their ability to help people…
STAT+: What FDA mandate? Sun Pharma halts shipments from a plant with a troubled history
In a fresh sign of quality-control problems in the Indian pharmaceutical industry, the U.S. Food…
STAT+: Gilead defeats federal government in closely watched battle over patents for HIV prevention pills
A U.S. court jury handed a major win to Gilead Sciences on Tuesday in a…
STAT+: Pharmalittle: Big pharma maps legal strategy against U.S. drug pricing reform; U.S. pharma layoffs continue to climb
Top of the morning to you, and a fine one it is. The sun is…
STAT+: Q&A: Sen. Sanders on insulin costs and his committee’s generic drug kerfuffle
WASHINGTON — Wednesday’s Senate hearing on high costs for insulin “is not the end” of…
STAT+: EQRX abandons business plan around drug pricing, cuts jobs and programs
EQRx, a company that aimed to lower drug prices by introducing inexpensive me-too medicines, said…
‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs
Amid rising demand for drugs like Wegovy, Ozempic, and Mounjaro that can lead to significant…
.jpg)
STAT+: Pharmalittle: FDA panel to review over-the-counter birth control pill; Alzheimer’s drugs may lead to haves and have-nots
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Opinion: The amoxicillin shortage continues to force pediatricians and families to scramble
“So, you don’t have it in liquid form?” I asked. The answer, as usual, was…
STAT+: Doudna talks cost, access issues looming over first CRISPR therapy
Jennifer Doudna may be just months away from seeing the first CRISPR-based therapy gain approval,…
STAT+: Pharmalittle: Pfizer and Valneva delay application for Lyme vaccine; Moderna adjusts price for Covid-19 shot
And so, another working week will soon draw to a close. Not a moment too…
STAT+: NIH grant recipients often fail to disclose agency support in patent applications
The National Institutes of Health may be the largest public funder of biomedical research in…
STAT+: Gilead foresees more growth in its HIV drugs
Gilead Sciences is famous — or perhaps, notorious — for its cure for hepatitis C….
STAT+: Scientific research will be threatened unless NIH overhauls systems for tracking non-human primates, report warns
A worsening shortage of non-human primates and an inadequate government response threatens to undermine biomedical…
STAT+: A new list ranks large pharmaceutical companies by research and development
If you want a large pharmaceutical company to invent a new drug, your best bet…
12,000 diseases lack treatments. One doctor thinks generics could yield cures
SAN FRANCISCO — About a decade ago, David Fajgenbaum thought his life was over. He…
STAT+: Pharmalittle: FDA OKs first RSV vaccine for older adults; Lilly Alzheimer’s data puts pressure on Medicare
Rise and shine, another busy day is on the way. We can tell by the…
Amid booming demand, Novo to hold back some doses of obesity drug Wegovy for new U.S. patients
Novo Nordisk, the maker of the wildly popular obesity drug Wegovy, said Thursday it would…
STAT+: New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced…
STAT+: CAR-T research is flourishing but is hampered by outdated precautions, experts say
Twenty years ago, CAR-T cell therapy was not quite “believed in,” said Michel Sadelain, director…
STAT+: What the Covid-19 pandemic can teach us about drug patents
Inventing treatments and vaccines is only part of the battle in an epidemic and pandemic,…
STAT+: Pharmalittle: Lilly’s Alzheimer’s drug slowed cognitive decline; most EU countries back plan to push production of key drugs
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Disagreements and digs upend an otherwise bipartisan hearing on PBM reform
WASHINGTON — The first Senate health committee markup under Chairman Bernie Sanders (I-Vt.) and ranking…
STAT+: Pharmalittle: Senate PBM reform bill delays effective date; Gilead and HHS square off in court over HIV patents
Good morning, everyone, and how are you today? Steely skies are hovering this morning over…
STAT+: A battle between Gilead and the U.S. government over patents on HIV prevention pills goes to trial
After years of sparring, the federal government and Gilead Sciences will square off in a…
STAT+: Most of Canada’s public research universities get bad grades for ensuring access to drugs they discover
Despite significant public funding, most of the 15 largest public research universities in Canada failed…
STAT+: Senators delay start date for possible PBM reforms
WASHINGTON — Pharmacy benefit managers may have gotten themselves a slight reprieve. Senators drafting reforms to…
STAT+: Pharmalittle: More biotechs are betting on obesity; Pfizer RSV vaccine faces hurdles in low-income countries
Good morning, everyone, and nice to see you again after a week-long respite in which…
STAT+: Sam Waksal and Jeremy Levin plot ‘the turnaround story of the century’
Over glasses of Chablis at Fleming by Le Bilboquet in Manhattan, two longtime friends and…
STAT+: Pharmalittle: Amgen ends two lupus programs; Illumina sequencers have security vulnerability
Hello and happy Friday, with STAT reporter Andrew Joseph here steering the ship in place…
STAT+: Covid-19 burnished pharma’s reputation among patient groups, but access to medicines is now an issue
In the wake of the Covid-19 pandemic, the pharmaceutical industry enjoyed something of an afterglow,…
STAT+: Pharmalittle: Lilly’s Mounjaro helped people lose 15.7% of body weight; Sanofi earnings boosted by Dupixent
Good morning everyone, from STAT reporter Andrew Joseph here filling in for Ed. Or, if…
STAT+: Pharma executives flood Bill Cassidy with campaign cash
WASHINGTON — Sen. Bill Cassidy’s new perch as the top Republican on the Senate health…
STAT+: EU releases proposed pharma overhaul, cutting period of market exclusivity
LONDON — The European Commission on Wednesday unveiled a long-awaited proposed update for how the…
STAT+: Pharmalittle: EU unveils sweeping pharma reforms; new eye drug helps Roche beat the street
Hello, everyone. Damian Garde here, filling in for Ed Silverman once more as the working…
Opinion: STAT+: At-home clinical trials are the future
In the early days of the Covid-19 pandemic, much of the clinical trials industry came…
.jpg)
STAT+: Medicare official insists drug price negotiation will consider value of drugs
WASHINGTON — When Medicare starts negotiating drug prices, it will take into account how important…
STAT+: Sens. Bernie Sanders, Bill Cassidy reach deal on PBM, generic reform
WASHINGTON — Senate health committee leaders Bernie Sanders and Bill Cassidy on Tuesday announced an agreement…
With little FDA oversight, melatonin supplements vary widely in actual dosage, study finds
WASHINGTON — Consumers turning to melatonin gummies to get some help falling asleep might be…
STAT+: Pharmalittle: Novartis boosts its sales and profit outlook; Biogen trims its drug pipeline
Good morning, one and all. Damian Garde here, filling in for Ed Silverman on an…
STAT+: Maryland pushes first-of-its-kind bill to promote alternatives to animals in biomedical research
Amid a push to use fewer animals in medical research, Maryland is on the verge…
STAT+: Pharmalittle: Weight-loss drug makers lobby Congress for Medicare coverage; Europe braces for new pharma legislation
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…